Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
YTH domain-containing protein 1 (YTHDC1) is a nuclear RNA-binding protein encoded by the human *YTHDC1* gene. It plays a critical role in regulating alternative splice site selection during pre-mRNA processing, localizing to dynamic subnuclear compartments known as "YT bodies" that appear during S-phase and disperse in mitosis. The defining feature of this family is the highly conserved YTH domain, which binds single-stranded RNA motifs—especially those containing N6-methyladenosine (m6A) modifications—thereby influencing exon inclusion or exclusion in mature transcripts. Through its control over alternative splicing, particularly of genes involved in tumorigenesis such as VEGF, BRCA1, and progesterone receptor, it has been implicated in cancer biology. In prostate cancer specifically, it interacts with metadherin to modulate tumor-related gene splicing. The broader family of YTH proteins are found only in eukaryotes and are key regulators of mRNA fate via recognition of m6A marks on RNAs[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on YTH domain-containing protein 1 (YTHDC1).